

<Organisation Details>
<Organisation Address>
<Organisation Details>
<Today's date>

<Patient Name>
<Patient Address>

Dear <Patient Name>

DOB: <Date of Birth> NHS No: <NHS number>

RE: Changes to your prescription for canagliflozin, empagliflozin or ertugliflozin

Our records show that you are currently prescribed one of the following medicines: canagliflozin, empagliflozin or ertugliflozin.

In line with NHS England recommendations, NHS Dorset have asked all GP practices to review the prescribing of these medicines and switch patients to dapagliflozin tablets.

[Dapagliflozin](#) is in the same therapeutic class as your existing medication (SGLT-2 inhibitors) and has a comparable clinical effect and safety profile but is the NHS England preferred choice. Therefore, we do not expect you to have any adverse effects because of this change but use of dapagliflozin will allow a greater number of patients to receive treatment.

Please read the label and patient information leaflet provided, before starting this new medication and finish your old supply first.

If you have any questions regarding this change, please speak to your community pharmacist or GP team.

Yours sincerely

<GP Name>
<Organisation Details>